URGN PDUFA decision: a positive outcome, +51.8%

On June 12, 2025, UroGen Pharma Ltd. reached its PDUFA decision. The result was a positive outcome, and the stock moved +51.8% in the window around the event. It had already run -30.8% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.